Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales

Swiss pharmaceutical company Novartis reported better-than-expected sales in Q4, with net sales rising 16% to $13.2 billion, exceeding analyst estimates. However, full-year sales fell short of guidance at $50.32 billion, while core operating income for 2024 increased to $19.5 billion. CEO Vas Narasimhan highlighted the company’s strong financial performance and growth outlook for 2025, focusing on advancing their development pipeline with over 30 assets for long-term growth.

Full Article